The cost implications of continuous glucose monitoring in pregnant women with type 1 diabetes in 3 Canadian provinces: a posthoc cost analysis of the CONCEPTT trial

Background: The Continuous Glucose Monitoring in Women with Type 1 Diabetes Pregnancy Trial (CONCEPTT) found improved health outcomes for mothers and their infants among those randomized to self-monitoring of blood glucose (SMBG) continuous monitoring (CGM) compared SMBG alone. In this study, we evaluated whether CGM or standard was more less costly from the perspective a third-party payer. Methods: We conducted posthoc analysis data CONCEPTT trial (Mar. 25, 2013, Mar. 22, 2016). Health care resource 215 pregnant women, SMBG, were collected 31 hospitals 7 countries. determined costs based on prices 3 Canadian provinces (Ontario, British Columbia, Alberta). primary outcome difference between groups mean total cost mother infant dyads, paid by each government (i.e., payer) randomization hospital discharge (time horizon). secondary included not governments (e.g., devices supplies). Results: lower group province (Ontario: $13 270.25 v. $18 465.21, [DMT] −$5194.96, 95% confidence interval [CI] −$9841 −$1395; BC: 480.57 762.17, DMT −$5281.60, CI −$9964 −$1382; Alberta: 294.39 674.45, −$5380.06, −$10 216 −$1490). There no outcome. Interpretation: Government are when is patient, driven reduced use neonatal intensive unit group; however, pay equipment, there overall SMBG. Governments should consider paying CGM, as it results maternal added cost. Trial registration: ClinicalTrials.gov, no. NCT01788527